GleamWall
中文EN

IBO IMPACT BIOMEDICAL INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1834105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY103.7%
TTM EPS YoY184.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,655.3%
Net margin4,247.4%
FCF margin—
EBITDA margin-9,657.9%

Returns

ROE—
ROA9.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.6%
Debt / equity0.00x
Current ratio0.04x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.07x
Accruals ratio8.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$21,000$3,000$7,000$7,000$18,000$7,000——
Cost of revenue$6,000$1,000—$422,000$1,000$1,000——
Gross profit$15,000$2,000—-$415,000$17,000$6,000——
R&D expense$35,000$76,000$46,000$110,000$52,000$75,000$103,000-$108,000
SG&A expense$156,000$167,000$1.62M$118,000$261,000$246,000$248,000$294,000
Operating income-$648,000-$702,000-$2.29M-$1.17M-$948,000-$1.15M-$1.01M-$26.23M
Interest expense———$0$262,000$260,000$271,000$270,000
Pretax income-$644,000-$700,000-$2.28M$2.65M-$1.48M-$14.35M-$1.28M-$27.10M
Net income-$645,000-$699,000-$2.29M$5.25M-$1.47M-$14.35M-$1.27M-$27.07M
EBITDA-$364,000-$418,000-$2.00M-$884,000-$660,000-$865,000-$727,000-$25.95M
EPS (basic)-0.08-0.01-0.02—-1.52-1.18-0.11—
EPS (diluted)-0.08-0.01-0.02—-1.52-1.18-0.11—
Balance sheet
Cash & equivalents$21,000$10,000$20,000$3,000$12,000$624,000$1.32M$2.00M
Receivables———$5,000$15,000$200,000$4,000$201,000
Inventory$56,000$62,000$63,000$63,000$485,000$486,000$489,000—
Current assets$102,000$320,000$377,000$411,000$917,000$1.48M$2.18M$2.45M
PP&E, net————$13,000$14,000$16,000$17,000
Goodwill———————$25.09M
Intangibles$16.14M$16.43M$16.71M$16.99M$17.28M$17.57M$17.85M$17.81M
Total assets$16.43M$16.75M$17.09M$17.41M$18.21M$19.06M$20.05M$20.29M
Current liabilities$2.37M$2.04M$1.69M$1.16M$23.79M$23.17M$9.97M$9.79M
Total liabilities$3.06M$2.73M$2.38M$1.85M$27.06M$26.44M$13.24M$13.05M
Shareholders' equity$10.12M$10.77M$11.46M$12.31M-$11.81M-$10.34M$3.84M$4.26M
Shares outstanding8.54M107.82M107.82M8.29M12.19M12.19M12.09M11.50M
Cash flow statement
Operating cash flow$11,000$470,000-$464,000$99,000-$613,000-$694,000-$682,000-$986,000
Investing cash flow$0$2,000-$1,000$1,000$1,000$0$1,000$0
Financing cash flow——$482,000————$317,000
Depreciation & amortization$284,000$284,000$285,000$286,000$288,000$288,000$283,000$279,000
Stock-based compensation$0$0$1.44M$8,000$2,000$2,000$2,000$19,000

Free plan shows the latest 8 periods; Pro shows all 18 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.